CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients
NCT03571360
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
42
Enrollment
OTHER
Sponsor class
Conditions
Non Small Cell Lung Cancer
Interventions
OTHER:
PD-L1 positive vs PD-L1 negative NSCLC patients
Sponsor
Medical University of Vienna